Dong-A PharmTech Signs Licensing Deal With Otechestvennye to Market Zydena in Russia
SEOUL, South Korea, Oct. 15 /PRNewswire/ -- Dong-A PharmTech
announced today the signing of a five-year US$50 Million contract with
Otechestvennye Lekarstva OJSC, to market in Russia Dong-A's erectile
dysfunction drug which is currently sold in Korea under the brand name of
Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2009 and Updates 2009 Full Year Guidance
...se of $11.7 million, or 96.0%, compared with the prior year quarter. Included in the quarter ended March 31, 2009 was a $9.0 million payment to Dong-A pharmtech
Co. Ltd. upon the achievement of a developmental milestone under our existing agreement for udenafil, an orally administered product for the treatment...
Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008
...th the prior year quarter. Included in R&D in the quarter ended December 31, 2008 was a $2.0 million expense to acquire certain rights from Dong-A pharmtech
Co. Ltd. to develop and market its orally-administered udenafil product for the treatment of erectile dysfunction ("ED"). Excluding this $2.0 million ...
Warner Chilcott and Dong-A Sign U.S. License Agreement For Erectile Dysfunction Treatment
...ILTON, Bermuda, Jan. 6 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX ) today announced that it has signed an agreement with Dong-A pharmtech
Co. Ltd., based in Korea, to develop and market their orally-administered udenafil product, a phosphodiesterase type 5 (PDE5) inhibitor for the treatm...
Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
SEOUL, South Korea, Feb. 25 /PRNewswire/ -- Dong-A PharmTech
announced today that its European licensee, Dr. Falk Pharma, has initiated
a 200 patient, phase 2 proof of concept clinical study to investigate the
use of udenafil, a long acting phosphodiesterase type 5 inhibitor, for
Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil,
Its New Long Acting Drug For Erectile Dysfunction
All Endpoints Met - Up to 88% Efficacy
SEOUL, Korea, March 28, 2007 /PRNewswire/ -- Dong-A PharmTech
Co., Ltd. announced today that it has completed a 340 patient phase
2b "at-home" clinical study for udenafil, its new long acting (12
hour half-life) oral phosphodiesterase type 5 (PDE5) inhibitor ...